Education
About Us
Working with TipRanks
Follow Us
Uni-Bio Science Group Ltd. (HK:0690)
:0690
RESEARCH TOOLSreports
0690 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$0.05 - HK$0.17
Previous CloseN/A
Volume1.74M
Average Volume (3M)27.39M
Market Cap
HK$947.18M
Enterprise ValueHK$300.49M
Total Cash (Recent Filing)HK$183.90M
Total Debt (Recent Filing)HK$115.19M
Price to Earnings (P/E)11.8
Beta-0.18
Next Earnings
Aug 28, 2025EPS EstimateN/A
Last Dividend Ex-Date
May 28, 2025Dividend Yield1.74%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding5,971,228,000
10 Day Avg. Volume32,171,339
30 Day Avg. Volume27,387,537
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Uni-Bio Science Group Ltd. News
0690 FAQ
What was Uni-Bio Science Group Ltd.’s price range in the past 12 months?
Uni-Bio Science Group Ltd. lowest stock price was HK$0.05 and its highest was HK$0.17 in the past 12 months.
What is Uni-Bio Science Group Ltd.’s market cap?
Uni-Bio Science Group Ltd.’s market cap is HK$947.18M.
When is Uni-Bio Science Group Ltd.’s upcoming earnings report date?
Uni-Bio Science Group Ltd.’s upcoming earnings report date is Aug 28, 2025 which is in 5 days.
How were Uni-Bio Science Group Ltd.’s earnings last quarter?
Uni-Bio Science Group Ltd. released its earnings results on Mar 27, 2025. The company reported HK$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.003.
Is Uni-Bio Science Group Ltd. overvalued?
According to Wall Street analysts Uni-Bio Science Group Ltd.’s price is currently Overvalued.
Does Uni-Bio Science Group Ltd. pay dividends?
Uni-Bio Science Group Ltd. pays a Notavailable dividend of HK$0.003 which represents an annual dividend yield of 1.74%. See more information on Uni-Bio Science Group Ltd. dividends here
What is Uni-Bio Science Group Ltd.’s EPS estimate?
Uni-Bio Science Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Uni-Bio Science Group Ltd. have?
Uni-Bio Science Group Ltd. has 5,971,228,000 shares outstanding.
What happened to Uni-Bio Science Group Ltd.’s price movement after its last earnings report?
Uni-Bio Science Group Ltd. reported an EPS of HK$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 14.286%.
Which hedge fund is a major shareholder of Uni-Bio Science Group Ltd.?
Currently, no hedge funds are holding shares in HK:0690
Uni-Bio Science Group Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
213.72%
12-Months-Change
Fundamentals
Return on Equity
28.40%
Trailing 12-Months
Asset Growth
26.23%
Trailing 12-Months
Company Description
Uni-Bio Science Group Ltd.
Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, an EGF eye drop for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Bokangtai, a mitiglinide tablet for the treatment of Type 2 diabetes, as well as Boshutai, an oral anti-diabetic drug targeting patients with pre-diabetes condition. It is also developing prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; and rhPTH 1-34 (Uni-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agonist, a non-insulin treatment candidate for the treatment of Type 2 diabetes. The company was founded in 2001 and is headquartered in Sha Tin, Hong Kong.
Technical Analysis
Kintor Pharmaceutical Ltd
―
3D Medicines, Inc.
―
JW (Cayman) Therapeutics Co. Ltd.
―
Sirnaomics Ltd.
―
Transcenta Holding Limited
―